SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

Clinical trial NCT05245058 · RECRUITING

Trial details

NCT number: NCT05245058
Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd
Status: RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

HER2-positive Advanced Solid Tumors

Start date: 2022-01-21
Primary completion: 2026-12-21
Enrollment: 150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.